JP2006503588A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503588A5
JP2006503588A5 JP2004569752A JP2004569752A JP2006503588A5 JP 2006503588 A5 JP2006503588 A5 JP 2006503588A5 JP 2004569752 A JP2004569752 A JP 2004569752A JP 2004569752 A JP2004569752 A JP 2004569752A JP 2006503588 A5 JP2006503588 A5 JP 2006503588A5
Authority
JP
Japan
Prior art keywords
diabetes
type
therapeutic agent
agent according
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004569752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503588A (ja
JP4873860B2 (ja
Filing date
Publication date
Priority claimed from US10/378,094 external-priority patent/US7176278B2/en
Application filed filed Critical
Publication of JP2006503588A publication Critical patent/JP2006503588A/ja
Publication of JP2006503588A5 publication Critical patent/JP2006503588A5/ja
Application granted granted Critical
Publication of JP4873860B2 publication Critical patent/JP4873860B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004569752A 2002-08-30 2003-08-28 改変トランスフェリン融合タンパク質 Expired - Fee Related JP4873860B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40697702P 2002-08-30 2002-08-30
US60/406,977 2002-08-30
US10/378,094 US7176278B2 (en) 2001-08-30 2003-03-04 Modified transferrin fusion proteins
US10/378,094 2003-03-04
PCT/US2003/026818 WO2004020405A2 (en) 2002-08-30 2003-08-28 Modified transferrin fusion proteins

Publications (3)

Publication Number Publication Date
JP2006503588A JP2006503588A (ja) 2006-02-02
JP2006503588A5 true JP2006503588A5 (enExample) 2006-10-19
JP4873860B2 JP4873860B2 (ja) 2012-02-08

Family

ID=31978395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004569752A Expired - Fee Related JP4873860B2 (ja) 2002-08-30 2003-08-28 改変トランスフェリン融合タンパク質

Country Status (9)

Country Link
US (1) US20060130158A1 (enExample)
EP (1) EP1545595B1 (enExample)
JP (1) JP4873860B2 (enExample)
CN (3) CN102268094A (enExample)
AT (1) ATE473011T1 (enExample)
AU (2) AU2003262886A1 (enExample)
DE (1) DE60333306D1 (enExample)
ES (1) ES2347144T3 (enExample)
WO (1) WO2004020454A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CN1628126A (zh) * 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2007512001A (ja) * 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
EA200700391A1 (ru) * 2004-08-03 2007-10-26 Байорексис Текнолоджи, Инк. Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
US20090275481A1 (en) * 2005-06-17 2009-11-05 Pfizer, Inc. Anchored Transferrin Fusion Protein Libraries
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP2463295A1 (en) * 2006-05-22 2012-06-13 The Regents of The University of California Compositions and methods for the delivery of oxygen
CN101088502B (zh) * 2006-06-16 2012-11-21 中国科学院化学研究所 一种含有转铁蛋白和槲皮素的结合物的混合溶液及其用途
CA2657277C (en) 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
DK2046826T3 (da) * 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
CN101578373A (zh) * 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
EP2114999A2 (en) 2006-12-12 2009-11-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
US9034341B2 (en) * 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US9644197B2 (en) * 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
SG11201509566RA (en) * 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
WO2015006337A2 (en) * 2013-07-08 2015-01-15 Nanjingjinsirui Science & Technology Biology Corporation Compositions and methods for increasing protein half-life in a serum
WO2015023649A2 (en) * 2013-08-12 2015-02-19 3M Innovative Properties Company Peptides for enhancing transdermal delivery
KR102058864B1 (ko) 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
PL3092251T3 (pl) * 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
JP2015224327A (ja) * 2014-05-29 2015-12-14 花王株式会社 繊維製品用洗浄剤組成物
KR102618312B1 (ko) * 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CN110167585B (zh) * 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
TWI791006B (zh) * 2016-12-26 2023-02-01 日商Ｊｃｒ製藥股份有限公司 包含bdnf之融合蛋白質
RS63818B1 (sr) * 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CN106967171B (zh) * 2017-02-23 2021-04-27 郑州大学 一种全人源重组CD40L单抗Fab片段及其制备方法
CN107010616B (zh) * 2017-04-13 2019-04-02 浙江理工大学 一种具有靶向传递功能的纳米药物载体的制备方法
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
BR112020005271A2 (pt) * 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
AU2017435322A1 (en) * 2017-10-11 2020-04-30 Nanjing Legend Biotech Co., Ltd. Compositions and methods for increasing protein half-life in a serum
BR112020013921A2 (pt) * 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
CN112312922B (zh) * 2018-06-21 2025-04-11 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物
CN109180819A (zh) * 2018-09-14 2019-01-11 苏州康宇生物科技有限公司 一种胰岛素衍生物的制备方法
US20220002752A1 (en) * 2018-11-13 2022-01-06 Denovo Biopharma Llc Recombinant vectors comprising genes for binding domains and secretable peptides
WO2021081485A1 (en) * 2019-10-25 2021-04-29 Northwestern University Cell-free extract preparation protocol for enrichment of membrane vesicles and increased glycoprotein yields
CN111948388B (zh) * 2020-08-18 2022-03-22 山东农业大学 一种检测腐败梭菌的胶体金试纸条及其制备方法和应用
CN112661862B (zh) * 2020-12-25 2023-03-31 深圳大学 一种融合蛋白及其制备方法和应用
CN113267631A (zh) * 2021-05-17 2021-08-17 江苏普若维生物技术有限责任公司 一种检测TNF-α的电化学试剂盒制备方法
WO2023142109A1 (zh) * 2022-01-30 2023-08-03 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用
KR20250114322A (ko) * 2022-12-02 2025-07-29 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-tfr1 항체 및 이의 용도
CN118931931B (zh) * 2024-07-23 2025-02-21 中国农业科学院北京畜牧兽医研究所 一种产气荚膜梭菌epsilon毒素-铁蛋白纳米颗粒抗原的制备方法
CN122080239B (zh) * 2026-04-22 2026-07-17 华中农业大学 一种动态共价交联双蛋白及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
WO1982002715A1 (fr) * 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US5026651A (en) * 1985-04-25 1991-06-25 Board Of Regents, The University Of Texas System Methods and compositions for the production of human transferrin
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5986067A (en) 1991-02-08 1999-11-16 The University Of Vermont And State Agricultural College Recombinant transferrins, transferrin half-molecules and mutants thereof
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
CA2110404A1 (en) * 1991-05-31 1992-12-10 Christina Teng Human lactoferrin
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5455933A (en) * 1993-07-14 1995-10-03 Dell Usa, L.P. Circuit and method for remote diagnosis of personal computers
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5849293A (en) * 1996-01-11 1998-12-15 Cornell Research Foundation, Inc. Use of human transferrin in controlling insulin levels
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6380362B1 (en) * 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
JP2002247847A (ja) * 2001-02-20 2002-08-30 Internatl Business Mach Corp <Ibm> Ａｃアダプタ、電源供給装置、電気機器、および電源供給装置の制御方法
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CN1628126A (zh) * 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
EP1407985B1 (en) * 2002-10-11 2005-12-28 Habasit AG Conveyor belt module with high friction surface
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins

Similar Documents

Publication Publication Date Title
JP2003503454A5 (enExample)
JP2006524283A5 (enExample)
JP2005519316A5 (enExample)
JP2006507281A5 (enExample)
JP2006515626A5 (enExample)
JP2005526147A5 (enExample)
JP2002532112A5 (enExample)
JP2005526058A5 (enExample)
JP2003520232A5 (enExample)
NL1029015A1 (nl) Therapeutische verbindingen.
JP2007520565A5 (enExample)
JP2005515295A5 (enExample)
JP2005510235A5 (enExample)
JP2006511228A5 (enExample)
JP2006506499A5 (enExample)
JP2006507484A5 (enExample)
JP2004035399A5 (enExample)
JP2004529205A5 (enExample)
RU2002107079A (ru) Вещество, обладающее седативным действием
JP2009504909A5 (enExample)
JP2002240244A5 (enExample)
JP2008519810A5 (enExample)
JP2008517002A5 (enExample)
RU2003110288A (ru) Вещество, обладающее антидепрессивной активностью
JP2005061961A5 (enExample)